News headlines about Pro-Dex (NASDAQ:PDEX) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pro-Dex earned a news impact score of 0.21 on Accern’s scale. Accern also gave news articles about the medical instruments supplier an impact score of 47.5043982440701 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of Pro-Dex (PDEX) remained flat at $$7.00 on Friday. The company’s stock had a trading volume of 2,617 shares, compared to its average volume of 8,409. The firm has a market capitalization of $30.52, a PE ratio of 5.51 and a beta of -0.37. Pro-Dex has a 1 year low of $4.30 and a 1 year high of $8.00.
COPYRIGHT VIOLATION NOTICE: This story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/18/pro-dex-pdex-getting-somewhat-positive-media-coverage-accern-reports.html.
Pro-Dex, Inc (Pro-Dex) designs and produces surgical and dental instruments and motion control products used in the medical, factory automation and scientific research industries. The Company operates through four segments: Pro-Dex, OMS, Fineline and Engineering Services Division (ESD). The Pro-Dex segment provides primarily medical and dental instruments using shared production and assembly machines and workforce.
Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.